Editorial Commentary: Tivozanib versus sorafenib in patients with advanced renal cell carcinoma (TIVO-3): a phase 3, multicentre, randomised, controlled, open-label study.

ABSTRACT:

SUBMITTER: Westerman ME 

PROVIDER: S-EPMC7475466 | biostudies-literature | 2020 Aug

REPOSITORIES: biostudies-literature